New drug may tame immunotherapy skin rash without steroids
NCT ID NCT06715982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether JAK inhibitors can safely and effectively treat severe skin rashes caused by immune checkpoint inhibitors in cancer patients. The goal is to relieve symptoms without using steroids, which can weaken the anti-cancer effect of immunotherapy. The study will enroll 35 adults with solid tumors who have developed grade 3-4 dermatitis from their cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JAK inhibitor (upadacitinib)
- What this could lead to
- If it works, this could offer a steroid-free way to manage severe skin rashes caused by immunotherapy, potentially allowing patients to continue cancer treatment.
- What could go wrong
- This is a small, early-phase trial with only 35 participants and no comparison group, so results may not apply broadly. JAK inhibitors also carry risks like infection and blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quzhou people's hospital
RECRUITINGQuzhou, Zhejiang, 324000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.